PL3677261T3 - Sposób podawania inhibitorów proteazy serynowej do żołądka - Google Patents

Sposób podawania inhibitorów proteazy serynowej do żołądka

Info

Publication number
PL3677261T3
PL3677261T3 PL19209258.3T PL19209258T PL3677261T3 PL 3677261 T3 PL3677261 T3 PL 3677261T3 PL 19209258 T PL19209258 T PL 19209258T PL 3677261 T3 PL3677261 T3 PL 3677261T3
Authority
PL
Poland
Prior art keywords
stomach
administration
protease inhibitors
serine protease
serine
Prior art date
Application number
PL19209258.3T
Other languages
English (en)
Inventor
Geert Schmid-Schoenbein
Andrew Lee
Jeng Wei
Original Assignee
Leading BioSciences, Inc.
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leading BioSciences, Inc., The Regents Of The University Of California filed Critical Leading BioSciences, Inc.
Publication of PL3677261T3 publication Critical patent/PL3677261T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL19209258.3T 2010-09-23 2011-09-23 Sposób podawania inhibitorów proteazy serynowej do żołądka PL3677261T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38579810P 2010-09-23 2010-09-23
US201161529052P 2011-08-30 2011-08-30

Publications (1)

Publication Number Publication Date
PL3677261T3 true PL3677261T3 (pl) 2023-10-16

Family

ID=45874410

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19209258.3T PL3677261T3 (pl) 2010-09-23 2011-09-23 Sposób podawania inhibitorów proteazy serynowej do żołądka

Country Status (7)

Country Link
US (5) US9504736B2 (pl)
EP (2) EP3677261B8 (pl)
KR (1) KR101820977B1 (pl)
CA (1) CA2812299C (pl)
ES (1) ES2951828T3 (pl)
PL (1) PL3677261T3 (pl)
WO (1) WO2012040595A2 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2951828T3 (es) 2010-09-23 2023-10-25 Leading Biosciences Inc Administración de inhibidores de serina proteasa al estómago
WO2015148474A1 (en) * 2014-03-25 2015-10-01 Leading BioSciences, Inc. Compositions for the treatment of autodigestion
US20150297619A1 (en) * 2014-04-17 2015-10-22 The Regents Of The University Of California Methods and compositions for preserving the mucosal barrier
CN113908281B (zh) 2016-01-11 2023-09-15 恒翼生物医药(上海)股份有限公司 用于治疗和预防粘连及肠梗阻的组合物和方法
WO2019084186A1 (en) * 2017-10-24 2019-05-02 Leading BioSciences, Inc. COMPOSITIONS AND METHODS FOR REGULATING GLUCOSE
BE1025996A9 (fr) 2018-01-19 2020-05-11 Hyloris Dev Sa Solution orale d’acide tranexamique
US10980757B2 (en) 2018-09-06 2021-04-20 RTU Pharma SA Ready-to-use tranexamic acid intravenous solution
US20250099412A1 (en) * 2022-01-18 2025-03-27 The Regents Of The University Of California Method of inhibiting degrading protease activity in aging
WO2024124212A1 (en) * 2022-12-08 2024-06-13 The Regents Of The University Of California Devices and methods for detection of disease biomarkers and therapeutic effectiveness

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56158707A (en) * 1980-04-08 1981-12-07 Lion Corp Composition for oral use
JP3496158B2 (ja) 1993-01-26 2004-02-09 東洋カプセル株式会社 トラネキサム酸配合ゼラチンカプセル製剤
US5578568A (en) 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
DE19617369A1 (de) 1996-04-30 1997-11-06 Immuno Ag Lagerstabile Fibrinogen-Präparate
JP3940209B2 (ja) * 1996-11-14 2007-07-04 株式会社資生堂 可溶化化粧料
US6121232A (en) 1997-01-31 2000-09-19 Omrix Biopharmaceuticals Sa Stabilized mixture comprising fibrinogen
WO1999008514A1 (en) 1997-08-20 1999-02-25 Lxr Biotechnology, Inc. Compositions containing polyethylene glycol and uses thereof
TWI243687B (en) 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
DE10025001A1 (de) 2000-05-22 2001-11-29 Aventis Behring Gmbh Gewebekleber mit verbesserten anti-adhäsiven Eigenschaften
US7276235B2 (en) 1998-11-18 2007-10-02 Zlb Behring Gmbh Tissue glue with improved antiadhesive properties
EP1204870B1 (en) * 1999-08-02 2010-01-20 Duke University Method for determining physiological effects of hemoglobin
US6534283B1 (en) 1999-11-24 2003-03-18 The Regents Of The University Of California Method for treatment and prevention of physiological shock
US6708822B1 (en) 1999-11-30 2004-03-23 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US20030144212A1 (en) 2000-07-06 2003-07-31 Hoffman Keith B Use of serine protease inhibitors to inhibit pathophysiology and neuropathology in a host
JP4044748B2 (ja) 2001-10-17 2008-02-06 サンスター株式会社 口腔用液体組成物
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
US20040018984A1 (en) 2002-07-17 2004-01-29 Mizuo Miyazaki Methods for preventing adhesion formation using protease inhibitors
GB0224909D0 (en) * 2002-10-25 2002-12-04 Norgine Europe Bv Colon cleansing compositions
BR0215954A (pt) 2002-11-26 2005-09-13 Uc Tech Métodos de redução da possibilidade de mortalidade em um animal, de expressão virulenta em um patógeno intestinal, e da expressão de adesina / lectina pa-i em uma célula bacteriana, de inibição de expressão de adesina / lectina pa-i em um patógeno intestinal, de ativação induzida por intestino de adesina / lectina pa-i, de mudança morfológica induzida por c4-hsl de um patógeno intestinal, e de aderência de célula bacteriana em um intestino de mamìfero, de melhoria de patogênese intestinal, de prevenção de uma doença ou condição anormal, de infecção de pele e respiratória, de uma doença sexualmente transmitida, de um distúrbio de trato digestivo, de perda de capacidade lactante em um animal, e de desenvolvimento de um distúrbio epitelial mediado por micróbio em uma animal de idade de amamentação, de irrigação de pelo menos uma porção do trato urinário, e para monitoração da administração de poli (etileno-glicol) (peg) a um animal, composição farmacêutica, kits para a prevenção ou tratamento terapêutico de sepsia derivada de intestino, e para a monitoração da administração de poli (etileno-glicol), e, preservativo
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
JP2005068076A (ja) 2003-08-25 2005-03-17 Tendou Seiyaku Kk トラネキサム酸類を含む外用液剤および清拭剤
US20090215898A1 (en) 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
EP1744767A4 (en) 2004-04-20 2008-08-13 Univ Chicago THERAPEUTIC DELIVERY SYSTEM WITH PEG-LIKE CONNECTION WITH HIGH MOLECULAR WEIGHT
US20080194611A1 (en) 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
AU2006255274A1 (en) 2005-06-03 2006-12-14 The University Of Chicago Modulation of microbial pathogen-host cell interactions
WO2007053194A2 (en) 2005-06-03 2007-05-10 The University Of Chicago Modulation of cell barrier dysfunction
US20090186949A1 (en) 2006-02-28 2009-07-23 The University Of Chicago Method for Treating Endothelial and Epithelial Cell Disorders by Administering High Molecular Weight PEG-Like Compounds
JP5465824B2 (ja) 2006-03-24 2014-04-09 第一三共ヘルスケア株式会社 医薬用製剤およびその製造方法
US20100179091A1 (en) 2007-02-20 2010-07-15 The Regents Of The University Of California Treatment of Conditions Related to Shock
JP5093841B2 (ja) * 2007-07-12 2012-12-12 株式会社 資生堂 不織布含浸化粧料
US9272034B2 (en) * 2007-10-04 2016-03-01 The Regents Of The University Of California Treatment of conditions related to shock
US20100226995A1 (en) 2007-11-12 2010-09-09 Debrouse Daniel R Microencapsulated bioactive agents for oral delivery and methods of use thereof
WO2010087874A1 (en) 2009-01-28 2010-08-05 Anazyme, Llc Compositions and methods for diagnosis of shock
WO2009100447A2 (en) * 2008-02-08 2009-08-13 The Regents Of The University Of California Detection of degradative enzymes and biomolecules in bodily fluids
WO2009132149A2 (en) * 2008-04-22 2009-10-29 The Regents Of The University Of California Treatment of conditions related to cecal ligation shock
AU2009244190B2 (en) * 2008-05-07 2016-02-25 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
JP5750096B2 (ja) 2009-03-23 2015-07-15 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 放射線照射誘発型上皮障害を予防および治療する方法
US7803762B1 (en) * 2009-08-20 2010-09-28 The Medicines Company Ready-to-use bivalirudin compositions
US20110060040A1 (en) 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
CN102834104A (zh) 2010-02-22 2012-12-19 优势医疗公司 治疗脑的出血性病状的方法和组合物
ES2951828T3 (es) 2010-09-23 2023-10-25 Leading Biosciences Inc Administración de inhibidores de serina proteasa al estómago
EP2621521A4 (en) 2010-10-02 2014-04-23 Univ California MINIMIZING DARMDYS FUNCTIONS
CN103099800B (zh) 2011-11-11 2017-08-04 日本乐敦制药株式会社 含有氨甲环酸的外用和内服用组合物
ES2375784B1 (es) 2011-12-22 2013-01-24 Laboratorios Kin S.A. Gel de ácido tranexámico
CN103565743B (zh) 2012-07-23 2016-06-22 上海市徐汇区中心医院 氨甲环酸皮肤外用纳米制剂及其制备方法和用途
WO2014028052A1 (en) 2012-08-17 2014-02-20 The University Of Chicago Materials and methods for preventing and treating anastomotic leaks
CN103054861A (zh) 2012-12-29 2013-04-24 北京阜康仁生物制药科技有限公司 一种含氨甲环酸的复方固体制剂
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
WO2015148474A1 (en) 2014-03-25 2015-10-01 Leading BioSciences, Inc. Compositions for the treatment of autodigestion
US20150297619A1 (en) 2014-04-17 2015-10-22 The Regents Of The University Of California Methods and compositions for preserving the mucosal barrier

Also Published As

Publication number Publication date
US20210177789A1 (en) 2021-06-17
US20130310325A1 (en) 2013-11-21
EP3677261A1 (en) 2020-07-08
ES2951828T3 (es) 2023-10-25
EP3677261B1 (en) 2023-06-07
EP2624823A4 (en) 2016-08-03
US9504736B2 (en) 2016-11-29
WO2012040595A9 (en) 2012-05-31
US11439611B2 (en) 2022-09-13
CA2812299A1 (en) 2012-03-29
US10772861B2 (en) 2020-09-15
EP3677261B8 (en) 2023-07-19
US20220370389A1 (en) 2022-11-24
CA2812299C (en) 2020-08-04
EP3677261C0 (en) 2023-06-07
KR20140017415A (ko) 2014-02-11
KR101820977B1 (ko) 2018-01-22
US20190175532A1 (en) 2019-06-13
US20170231935A1 (en) 2017-08-17
CN102821762A (zh) 2012-12-12
EP2624823A2 (en) 2013-08-14
US20200246291A9 (en) 2020-08-06
WO2012040595A2 (en) 2012-03-29
US10137100B2 (en) 2018-11-27

Similar Documents

Publication Publication Date Title
PL3677261T3 (pl) Sposób podawania inhibitorów proteazy serynowej do żołądka
HUE050079T2 (hu) Szerin-proteáz variánsokat tartalmazó készítmények és módszerek
EP2542074A4 (en) PHARMACEUTICAL COMBINATION ACTIVE AGENTS AS HCV REPLICATION INHIBITORS
ZA201307499B (en) Compositions and methods comprising serine protease variants
ZA201107852B (en) Lyophilization cakes of proteasome inhibitors
ZA201308086B (en) Derivatives of 1-anino-2-cyclopropylboronic acid
SMT202200034T1 (it) Composizione farmaceutica di carbetocina
EP2681200A4 (en) INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
EP2528895A4 (en) TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE
ZA201206456B (en) Uses of dgati inhibitors
PL2523938T3 (pl) Pochodne aminoakrydyny przydatne jako selektywne inhibitory proteazy 7 specyficznej dla ubikwityny
EP2632895A4 (en) HIV PROTEASE INHIBITORS
AP3787A (en) New form of administration of enkephalinase inhibitor
SG11201400102WA (en) Inhibitors of nedd8-activating enzyme
EP2635287A4 (en) NEDD8 ACTIVATOR ENZYME INHIBITOR ADMINISTRATION
ZA201300065B (en) Crystal of amide compound
FI20106135A0 (fi) Sieniperäisen seriiniproteaasin variantteja
EP2751141A4 (en) STABLE PACE4 INHIBITORS BASED ON PEPTIDE
SI2407155T1 (sl) Preparati na osnovi inekalcitola
PL2513060T3 (pl) Krystaliczna postać α karbabenzopirydu
GB201409877D0 (en) Composition pharmaceutical composition of protease inhibitors and production thereof
IL239208A0 (en) Compounds and methods for the purification of serine proteases
EP2536688A4 (en) STABLE DOSAGE FORMS OF LEVOMILNACIPRAN
AP2014007760A0 (en) Stabilized pharmaceutical formulations of a potentHCV inhibitor
TWM403124U (en) Improve structure of the HDMI connector